![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Trubion Pharmaceuticals (MM) | NASDAQ:TRBN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.60 | 0 | 01:00:00 |
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Expires: February 28, 2011 Estimated average burden hours per response... 0.5 |
|
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person
*
Hove Anders D |
2. Issuer Name
and
Ticker or Trading Symbol
Trubion Pharmaceuticals, Inc [ TRBN ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__ X __ Director _____ 10% Owner _____ Officer (give title below) __ X __ Other (specify below) Indirect 10% owner |
C/O VENROCK ASSOCIATES, 30 ROCKEFELLER PLAZA, ROOM 5508 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
NEW YORK, NY 10112 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 308367 | I | By Venrock Partners, L.P. (1) | |||||||
Common Stock | 1512111 | I | By Venrock Associates IV, L.P. (2) | |||||||
Common Stock | 37154 | I | By Venrock Entrepreneurs Fund IV, L.P. (3) |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Stock Option (right to purchase) | $6.63 | 5/28/2008 | A | 5000 | (4) | 5/28/2018 | Common Stock | 5000 | $0.00 | 5000 | D |
Explanation of Responses: | |
( 1) | Venrock Partners, L.P. is a limited partership, the general partner of which is Venrock Partners Management, LLC. The reporting person is a member of Venrock Partners Managment, LLC and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
( 2) | Venrock Associates IV, L.P. is a limited partership, the general partner of which is Venrock Partners Management, LLC. The reporting person is a member of Venrock Partners Managment, LLC and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
( 3) | Venrock Entrepreneurs Fund IV, L.P. is a limited partership, the general partner of which is VEF Management IV, LLC. The reporting person is a member of VEF Management IV, LLC and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
( 4) | Option vests 100% on May 15, 2009, subject to the individual's provision of service to the issuer on such date. |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
Hove Anders D
C/O VENROCK ASSOCIATES 30 ROCKEFELLER PLAZA, ROOM 5508 NEW YORK, NY 10112 |
X |
|
|
Indirect 10% owner |
Signatures
|
||
/s/ Michelle Burris as attorney-in-fact for Anders D. Hove | 5/29/2008 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Trubion Pharmaceuticals (MM) Chart |
1 Month Trubion Pharmaceuticals (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions